David R. Keefer - Jan 4, 2022 Form 4 Insider Report for Virios Therapeutics, Inc. (VIRI)

Role
Director
Signature
/s/ Greg Duncan, Attorney-in-Fact
Stock symbol
VIRI
Transactions as of
Jan 4, 2022
Transactions value $
$28,975
Form type
4
Date filed
1/5/2022, 02:12 PM
Previous filing
Jun 23, 2021
Next filing
Jun 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIRI Common Stock Purchase $29K +5K $5.80* 5K Jan 4, 2022 Direct F1
holding VIRI Common Stock 7.81K Jan 4, 2022 Ethica Group, LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.75 to $5.80, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F2 The securities are owned directly by Ethica Group, LLC ("Ethica"). The Reporting Person is managing member of Ethica and may be deemed to beneficially own the securities held directly by Ethica.